eFFECTOR Therapeutics, Inc.
NASDAQ:EFTR
0.04 (USD) • At close September 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | eFFECTOR Therapeutics, Inc. |
Symbool | EFTR |
Munteenheid | USD |
Prijs | 0.04 |
Beurswaarde | 188,176 |
Dividendpercentage | 0% |
52-weken bereik | 0.03 - 17.9 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Stephen T. Worland Ph.D. |
Website | https://effector.com |
An error occurred while fetching data.
Over eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)